Posts by: Patricia Inacio PhD

Patricia Inacio PhD

Patricia holds her Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She also served as a PhD student research assistant in the Laboratory of Doctor David A. Fidock, Department of Microbiology & Immunology, Columbia University, New York.

June 16, 2020June 16, 2020

DPX-Survivac Shows Durable Responses in Advanced Ovarian Cancers, Trial Data Show

News

A combination of IMV‘s immunotherapy DPX-Survivac plus intermittent low-dose cyclophosphamide leads to sustained responses in women with heavily-treated advanced ovarian cancer, with some responses lasting more than 10 months, updated ... Read more

June 9, 2020June 9, 2020

More Than Half of Patients Respond to VB-111 Chemo Combo, Trial Data Shows

News

VBL Therapeutic’s investigational therapy VB-111 (ofranergene obadenovec) continues to show promising response rates in women with platinum-resistant ovarian cancer, with more than half of patients enrolled in a Phase 3 ... Read more

April 1, 2020April 1, 2020

Acelarin Trial Shows Potential in Chemo-resistant Ovarian Cancer, But Study Ending

News

Treatment with Acelarin led to one complete response and two partial responses in heavily pre-treated women with platinum-resistant ovarian cancer, early results from a Phase 2 trial show. Full analysis of the study’s ... Read more

March 20, 2020March 20, 2020

China Reviewing Zejula as First-line Therapy for Ovarian Cancer

News

The Chinese regulatory agency has agreed to review Zai Lab‘s application asking that Zejula (niraparib) be approved as first-line maintenance therapy for women with ovarian cancer who are responding to ... Read more

March 4, 2020March 4, 2020

DPX-Survivac Shows Promise in Advanced OC, Early Phase 2 Data Show

News

Treatment with IMV‘s cancer vaccine DPX-Survivac, combined with intermittent low-dose cyclophosphamide, continues to show promise in women with recurrent, advanced ovarian cancer, updated results from a Phase 1/2 trial show. ... Read more

February 28, 2020February 28, 2020

COM701 Shows Promise in Treating Ovarian, Other Solid Tumors, Early Data Suggest

News

Treatment with Compugen‘s immune checkpoint inhibitor COM701, either alone or in combination with Opdivo (nivolumab), is well-tolerated in people with advanced solid tumors, including ovarian cancer, early Phase 1 trial results show. ... Read more

February 26, 2020February 27, 2020

Zejula as First-line Treatment for Advanced Ovarian Cancer Before FDA

News

The U.S. Food and Drug Administration (FDA) has accepted GSK‘s request to extend approval for Zejula (niraparib) to include as a first-line maintenance therapy for women with newly diagnosed and ... Read more

February 10, 2020February 10, 2020

France Adds Rubraca for Relapsed Platinum-sensitive Ovarian Cancer to Reimbursed Treatments

News

Rubraca (rucaparib) is now available in France and eligible for reimbursement when used as a maintenance therapy by women with relapsed ovarian cancer who responded to platinum-based chemotherapy, regardless of their BRCA status, its developer, ... Read more

January 30, 2020February 5, 2020

Clinical Trial of DNA Decoy to Make Ovarian Cancer’s Zejula More Effective Set to Open

News

A Phase 1b/2 clinical trial testing Onxeo’s AsiDNA as a potential treatment to overcome resistance to Zejula (niraparib) in ovarian cancer patients is set to begin, part of an agreement ... Read more

December 20, 2019

Trial Seeks Participants to Study AVB-500 Plus Imfinzi in Platinum-resistant Ovarian Cancers

News

Aravive is recruiting participants for a Phase 1/2 clinical trial assessing a combination of its experimental treatment AVB-500 plus the immune checkpoint inhibitor Imfinzi (durvalumab) in women with platinum-resistant epithelial ... Read more